Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Zelira Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
Health & Biotech
Check Up: Aussie biotech Ternarx to pioneer next-gen cancer medicine, and recent ASX health winners
Health & Biotech
Weed Week: Getting a grip on the cannabis scene amid a pending regulatory shakeup
News
Rise and Shine: Everything you need to know before the ASX opens
News
Small Caps Lunch Wrap: Markets are down but who cares when these ASX penny stocks have gone quite mad
News
ASX Small Caps Lunch Wrap: Who might be losing their trading privileges this week?
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Small Caps Lunch Wrap: Has Japan unleashed a new colossal death robot this week?
Health & Biotech
ASX Health Stocks: Imricor installs key equipment at Swiss hospital
Health & Biotech
Weed Week: Massive study links cannabis to genetics and schizophrenia, and the best ASX weed stocks right now
Health & Biotech
Clinical results for ancient therapy help ASX cannabis stocks weed out competition
Health & Biotech
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Health & Biotech
ASX-listed Zelira is going head-to-head with Big Pharma. We spoke to its CEO about its place in a US$62 billion market
Health & Biotech
Weed Week: Storm before the calm as cannabis market set to boom after SAFE Banking Act passed
Health & Biotech
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
News
